TD Cowen analyst Dan Brennan lowered the firm’s price target on Exact Sciences (EXAS) to $82 from $90 and keeps a Buy rating on the shares. The firm said they reporrted a modest 3Q miss and a material guidance cut for 4Q as Commercial execution, weather (hurricanes) and slower productivity ramp were cited.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target lowered to $67 from $70 at Baird
- Exact Sciences price target lowered to $75 from $88 at BofA
- Exact Sciences price target lowered to $75 from $80 at Citi
- Exact Sciences price target lowered to $75 from $95 at Canaccord
- Exact Sciences Reports Strong Q3 Performance and Pipeline Advances